Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $15.70 in the prior trading day, Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) closed at $15.50, down -1.27%. In other words, the price has decreased by -$1.27 from its previous closing price. On the day, 2.04 million shares were traded.
Ratios:
Our goal is to gain a better understanding of ARWR by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.95 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 465.34. For the most recent quarter (mrq), Quick Ratio is recorded 5.15 and its Current Ratio is at 5.15. In the meantime, Its Debt-to-Equity ratio is 1.08 whereas as Long-Term Debt/Eq ratio is at 0.98.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on June 05, 2024, initiated with a Neutral rating and assigned the stock a target price of $31.
On December 04, 2023, BofA Securities started tracking the stock assigning a Buy rating and target price of $29.
On September 19, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $33.Citigroup initiated its Neutral rating on September 19, 2023, with a $33 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 11 ’25 when Anzalone Christopher Richard sold 50,800 shares for $11.49 per share. The transaction valued at 583,692 led to the insider holds 3,921,255 shares of the business.
Anzalone Christopher Richard sold 50,000 shares of ARWR for $543,500 on Apr 10 ’25. The Chief Executive Officer now owns 3,972,055 shares after completing the transaction at $10.87 per share. On Apr 09 ’25, another insider, Anzalone Christopher Richard, who serves as the Chief Executive Officer of the company, sold 40,322 shares for $10.07 each. As a result, the insider received 406,145 and left with 4,022,055 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3.93 while its Price-to-Book (P/B) ratio in mrq is 3.13.
Stock Price History:
Over the past 52 weeks, ARWR has reached a high of $30.41, while it has fallen to a 52-week low of $9.57. The 50-Day Moving Average of the stock is 8.26%, while the 200-Day Moving Average is calculated to be -14.84%.
Shares Statistics:
A total of 138.06M shares are outstanding, with a floating share count of 115.20M. Insiders hold about 16.58% of the company’s shares, while institutions hold 74.55% stake in the company.
Earnings Estimates
A comprehensive evaluation of Arrowhead Pharmaceuticals Inc (ARWR) is underway, with the input of 12.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.5, with high estimates of $1.05 and low estimates of -$1.48.
Analysts are recommending an EPS of between $1.57 and -$1.27 for the fiscal current year, implying an average EPS of -$0.18. EPS for the following year is -$3.45, with 13.0 analysts recommending between -$1.66 and -$4.72.
Revenue Estimates
A total of 15 analysts have provided revenue estimates for ARWR’s current fiscal year. The highest revenue estimate was $914.5M, while the lowest revenue estimate was $545.2M, resulting in an average revenue estimate of $698.31M. In the same quarter a year ago, actual revenue was $3.55MBased on 16 analysts’ estimates, the company’s revenue will be $285.94M in the next fiscal year. The high estimate is $466.95M and the low estimate is $94M.
